A prospective real-world study in NAFLD with diabetic dyslipidemia demonstrated that 24 weeks of saroglitazar 4 mg led to significant reductions in alanine aminotransferase (ALT), aspartate aminotransferase (AST), liver stiffness measurement (LSM), and controlled attenuation parameter (CAP), along with improvements in glycemic and lipid parameters, supporting its hepatometabolic mechanisms [11]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.